Nachrichten zur Edwards Lifesciences Corp. Aktie

Stifel raises Edwards Lifesciences stock to buy, target to $90 By Investing.com

Stifel raises Edwards Lifesciences stock to buy, target to $90…

Edwards Lifesciences exec sells $343,735 in stock By Investing.com

Edwards Lifesciences exec sells $343,735 in stock…

Is it Apt to Hold Edwards Lifesciences Stock in Your Portfolio Now?

Edward Lifesciences robust potential in Structural heart and long-term strategy instill optimism.…

EDWARDS ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Edwards Lifesciences Corp and Encourages Investors to Contact the Firm

NEW YORK, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights…

INVESTOR DEADLINE NEXT WEEK: Robbins Geller Rudman & Dowd LLP Announces that Edwards Lifesciences Corporation Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - EW

SAN DIEGO, Dec. 07, 2024 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that purchasers or…

EDWARDS ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Edwards Lifesciences Corp and Encourages Investors to Contact the Firm

NEW YORK, Dec. 05, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights…

EDWARDS LIFESCIENCES CORPORATION (NYSE: EW) INVESTOR ALERT: Bernstein Liebhard LLP Reminds Edwards Lifesciences Corporation Investors of Upcoming Deadline

EDWARDS LIFESCIENCES CORPORATION (NYSE: EW) INVESTOR ALERT: Bernstein Liebhard LLP Reminds Edwards Lifesciences Corporation Investors of Upcoming Deadline…

EDWARDS ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Edwards Lifesciences Corp and Encourages Investors to Contact the Firm

NEW YORK, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights…

EW INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that Edwards Lifesciences Corporation Investors with Substantial Losses Have Opportunity to Lead Securities Class Action Lawsuit

SAN DIEGO, Nov. 22, 2024 (GLOBE NEWSWIRE) -- The law firm of Robbins Geller Rudman & Dowd LLP…

EDWARDS ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Edwards Lifesciences Corp and Encourages Investors to Contact the Firm

NEW YORK, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights…

EW LEGAL UPDATE: Invest in Edwards Lifesciences and Lose Money? You may have been Affected by Fraud and are Urged to Contact BFA Law about the Class Action (NYSE:EW)

Edwards Lifesciences Corporation investors that lost money on their investment are encouraged to contact BFA Law before December 13, 2024…

EDWARDS ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Edwards Lifesciences Corp and Encourages Investors to Contact the Firm

NEW YORK, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights…

EW INVESTOR UPDATE: Did Edwards Lifesciences Mislead Investors Causing Losses? Contact BFA Law about the Pending Securities Fraud Lawsuit (NYSE:EW)

Edwards Lifesciences Corporation investors that lost money on their investment are encouraged to contact BFA Law before December 13, 2024…

Edwards Lifesciences Aktie: Überraschend vielversprechend

Die Edwards Lifesciences Aktie verzeichnete am 2. November 2024 einen erneuten Anstieg und setzte damit ihren positiven Trend der letzten…

EDWARDS LIFESCIENCES has been Sued for Securities Fraud after Stock Plummets 31%; Contact the Firm before December 13 Class Action Deadline (NYSE:EW)

Edwards Lifesciences Corporation investors that lost money on their investment are encouraged to contact BFA Law before December 13, 2024…

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against TD, Edwards, and UPS and Encourages Investors to Contact the Firm

NEW YORK, Oct. 28, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights…

Edwards Lifesciences Q3: Divesting Critical Care And Focusing On Structural Hearts

…

EW INVESTOR ALERT: Edelson Lechtzin LLP Urges Edwards Lifesciences Corporation (NYSE: EW) Shareholders to Seek Legal Counsel About the Pending Securities Fraud Class Action

Edelson Lechtzin LLP announces the filing of a securities fraud class action on behalf of all purchasers of Edwards Lifesciences…

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Elanco, Edwards, and UPS and Encourages Investors to Contact the Firm

NEW YORK, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights…

EW INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that Edwards Lifesciences Corporation Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

SAN DIEGO, Oct. 19, 2024 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that purchasers or…

EDWARDS LIFESCIENCES CORPORATION (NYSE: EW) INVESTOR ALERT: Investors With Large Losses in Edwards Lifesciences Corporation Should Contact Bernstein Liebhard LLP To Discuss Their Rights

EDWARDS LIFESCIENCES CORPORATION (NYSE: EW) INVESTOR ALERT: Investors With Large Losses in Edwards Lifesciences Should Contact Bernstein Liebhard LLP…

EDWARDS ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Edwards Lifesciences Corp and Encourages Investors to Contact the Firm

NEW YORK, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights…

EW INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Edwards Lifesciences Corporation Investors with Substantial Losses Have Opportunity to Lead the Edwards Lifesciences Class Action Lawsuit

SAN DIEGO, Oct. 14, 2024 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that purchasers or…

Is it the Right Time to Hold EW Stock in Your Portfolio Now?

Edward Lifesciences Critical Care divestiture bodes well for its Structural Heart portfolio. Yet, macroeconomic issues raise worry for its operations.…

Edwards Lifesciences Aktie: Leichter Rückgang trotz solider Aussichten

Die Edwards Lifesciences Aktie verzeichnete am 21. September 2024 einen leichten Rückgang von 0,57% auf 66,84 USD. Trotz dieses kleinen…

Edwards Lifesciences: Solvable Problems Offer Excellent Opportunities

…

BD Stock Falls After Acquisition of Edwards Critical Care Group

BDX expands its smart care portfolio by acquiring Edwards Lifesciences Critical Care group, now BD Advanced Patient Monitoring, strengthening AI-driven…

Should You Hold Edward Lifesciences (EW) in Your Portfolio Now?

Edward Lifesciences (EW) promising TAVR business and the Critical Care divestment move bode well in the long term.…

Edwards Lifesciences (EW) Q2 Earnings Meet Mark, Margins Crash

Edwards Lifesciences (EW) reports strong contributions from the TMTT product group in the second quarter of 2024.…

After-hours movers: Chipotle Mexican Grill, Ford, IBM, Edwards Lifesciences, and more By Investing.com

After-hours movers: Chipotle Mexican Grill, Ford, IBM, Edwards Lifesciences, and more…

Edwards Lifesciences Crumbles On Slashed TAVR Outlook

The company now expects full-year sales in its TAVR division to climb 5% to 7%.…

Edwards Lifesciences (EW) Buys Innovalve to Boost TMVR Solutions

Edwards Lifesciences (EW) exercises the option to acquire Innovalve Bio-Medical Ltd., strengthening its TMVR technology portfolio and addressing unmet…

Is a Beat Likely for Edwards Lifesciences (EW) in Q2 Earnings?

Edwards Lifesciences (EW) TMTT segments PASCAL platform is likely to have maintained strong growth momentum in the second quarter…

Edwards Lifesciences: Focus On The Heart

…

Aktienmarkt: Edwards Lifesciences-Aktie tritt auf der Stelle (85,6517 €)

Wenig Kursbewegung aktuell bei dem Anteilsschein von Edwards Lifesciences . Das Papier kostete zuletzt 91,47 US-Dollar. Die Wertschätzung der Investoren…